Cybin Inc. Appoints New Chief Medical Officer
Ticker: HELP · Form: 6-K · Filed: Jun 11, 2024 · CIK: 1833141
| Field | Detail |
|---|---|
| Company | Cybin INC. (HELP) |
| Form Type | 6-K |
| Filed Date | Jun 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, pharmaceuticals, clinical-development
TL;DR
Cybin beefs up medical team with new CMO, Dr. Amir Inamdar, to push psychedelic drug pipeline.
AI Summary
On June 11, 2024, Cybin Inc. filed a Form 6-K, announcing the appointment of Dr. Amir Inamdar as Chief Medical Officer. Dr. Inamdar brings extensive experience in psychedelic drug development and clinical trials to Cybin, aiming to advance the company's pipeline of psychedelic therapeutics.
Why It Matters
The appointment of a new Chief Medical Officer with specific experience in psychedelic drug development signals Cybin's continued commitment to advancing its clinical programs in this novel therapeutic area.
Risk Assessment
Risk Level: medium — The company operates in the highly regulated and evolving field of psychedelic therapeutics, which carries inherent clinical and regulatory risks.
Key Players & Entities
- Cybin Inc. (company) — Registrant
- Dr. Amir Inamdar (person) — Appointed Chief Medical Officer
- Doug Drysdale (person) — Chief Executive Officer
- June 11, 2024 (date) — Filing date and news release date
FAQ
Who has Cybin Inc. appointed as its new Chief Medical Officer?
Cybin Inc. has appointed Dr. Amir Inamdar as its new Chief Medical Officer.
What is the significance of Dr. Inamdar's appointment?
Dr. Inamdar brings extensive experience in psychedelic drug development and clinical trials, which is expected to advance Cybin's pipeline of psychedelic therapeutics.
When was this report filed with the SEC?
This report was filed on June 11, 2024.
What is Cybin Inc.'s principal executive office address?
Cybin Inc.'s principal executive office is located at 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9.
What form is Cybin Inc. filing?
Cybin Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer.
Filing Stats: 147 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2024-06-11 17:28:01
Filing Documents
- cybininc-form6xk06x11x2024.htm (6-K) — 11KB
- a06-11x2024svpclinicaldeve.htm (EX-99.1) — 19KB
- image_0.jpg (GRAPHIC) — 25KB
- 0001628280-24-027704.txt ( ) — 64KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2024. Commission File Number 001-40673 Cybin Inc. (Exact Name of Registrant as Specified in Charter) 100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CYBIN INC. (Registrant) Date June 11, 2024 By s Doug Drysdale Name Doug Drysdale Title Chief Executive Officer EXHIBIT INDEX 99.1 News Release dated June 11, 2024